Zoetis Competitors

Zoetis (NYSE:ZTS) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Zoetis and Johnson & Johnson's net margins, return on equity and return on assets.

Risk & Volatility

Zoetis has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Zoetis pays out 26.0% of its earnings in the form of a dividend. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Johnson & Johnson has raised its dividend for 59 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

90.2% of Zoetis shares are owned by institutional investors. Comparatively, 66.7% of Johnson & Johnson shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Zoetis and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Zoetis. Johnson & Johnson is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Zoetis and Johnson & Johnson, as provided by MarketBeat.

Zoetis presently has a consensus price target of $184.25, indicating a potential downside of 0.64%. Johnson & Johnson has a consensus price target of $185.70, indicating a potential upside of 12.88%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Zoetis.

Summary

Johnson & Johnson beats Zoetis on 10 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Insider & Institutional Ownership

64.2% of Pfizer shares are held by institutional investors. Comparatively, 90.2% of Zoetis shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Pfizer and Zoetis' net margins, return on equity and return on assets.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.9%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Pfizer pays out 70.3% of its earnings in the form of a dividend. Zoetis pays out 26.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Earnings and Valuation

This table compares Pfizer and Zoetis' gross revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Zoetis. Pfizer is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Pfizer has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Pfizer and Zoetis, as reported by MarketBeat.com.

Pfizer currently has a consensus target price of $40.2857, indicating a potential upside of 1.76%. Zoetis has a consensus target price of $184.25, indicating a potential downside of 0.64%. Given Pfizer's higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Zoetis.

Summary

Zoetis beats Pfizer on 11 of the 16 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Zoetis and Eli Lilly and, as reported by MarketBeat.

Zoetis currently has a consensus target price of $184.25, indicating a potential downside of 0.64%. Eli Lilly and has a consensus target price of $211.7143, indicating a potential downside of 5.11%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Eli Lilly and.

Profitability

This table compares Zoetis and Eli Lilly and's net margins, return on equity and return on assets.

Institutional & Insider Ownership

90.2% of Zoetis shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Zoetis and Eli Lilly and's revenue, earnings per share (EPS) and valuation.

Eli Lilly and has higher revenue and earnings than Zoetis. Eli Lilly and is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Zoetis has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.5%. Zoetis pays out 26.0% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Eli Lilly and has raised its dividend for 1 consecutive years.

Summary

Eli Lilly and beats Zoetis on 9 of the 17 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Zoetis and AbbVie, as reported by MarketBeat.

Zoetis currently has a consensus target price of $184.25, indicating a potential downside of 0.64%. AbbVie has a consensus target price of $119.4615, indicating a potential upside of 3.29%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Zoetis.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Zoetis pays out 26.0% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Zoetis and AbbVie's net margins, return on equity and return on assets.

Risk & Volatility

Zoetis has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Valuation & Earnings

This table compares Zoetis and AbbVie's revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Zoetis. AbbVie is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

90.2% of Zoetis shares are owned by institutional investors. Comparatively, 66.1% of AbbVie shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

AbbVie beats Zoetis on 10 of the 17 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Zoetis and Merck & Co., Inc., as reported by MarketBeat.com.

Zoetis presently has a consensus price target of $184.25, indicating a potential downside of 0.64%. Merck & Co., Inc. has a consensus price target of $96.1111, indicating a potential upside of 27.38%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Zoetis.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Zoetis pays out 26.0% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 43.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Merck & Co., Inc. has raised its dividend for 1 consecutive years.

Profitability

This table compares Zoetis and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Risk and Volatility

Zoetis has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Valuation and Earnings

This table compares Zoetis and Merck & Co., Inc.'s top-line revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than Zoetis. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

90.2% of Zoetis shares are held by institutional investors. Comparatively, 72.0% of Merck & Co., Inc. shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Zoetis on 9 of the 16 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 2.9%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Bristol-Myers Squibb pays out 30.4% of its earnings in the form of a dividend. Zoetis pays out 26.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 1 consecutive years and Zoetis has raised its dividend for 1 consecutive years.

Institutional & Insider Ownership

71.8% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 90.2% of Zoetis shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Zoetis' gross revenue, earnings per share (EPS) and valuation.

Zoetis has lower revenue, but higher earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Bristol-Myers Squibb and Zoetis, as provided by MarketBeat.

Bristol-Myers Squibb presently has a consensus price target of $72.8462, indicating a potential upside of 8.19%. Zoetis has a consensus price target of $184.25, indicating a potential downside of 0.64%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Zoetis.

Profitability

This table compares Bristol-Myers Squibb and Zoetis' net margins, return on equity and return on assets.

Volatility & Risk

Bristol-Myers Squibb has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Summary

Zoetis beats Bristol-Myers Squibb on 10 of the 17 factors compared between the two stocks.